Literature DB >> 21817948

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

Lauren J Stockman1, Aaron T Curns, Larry J Anderson, Gayle Fischer-Langley.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract disease among young children in the United States. RSV-associated hospitalization increased among children in the United States during 1980 through 1996. In this study, we updated national estimates of RSV hospitalization rates among US children through 2006.
METHODS: We conducted a retrospective analysis of hospital discharges for lower respiratory tract illness (LRTI) in children <5 years old from the National Hospital Discharge Survey. LRTI hospitalizations were identified by using International Classification of Diseases, Ninth Revision, Clinical Modification codes. RSV-coded hospitalizations were International Classification of Diseases, Ninth Revision, Clinical Modification codes 466.11, 480.1, and 079.6. RSV-associated hospitalizations were the sum of RSV-coded hospitalizations and a proportion of hospitalizations coded as bronchiolitis and pneumonia during the RSV season.
RESULTS: RSV-coded hospitalizations accounted for 24% of an estimated 5.5 million LRTI hospitalizations among children <5 years of age during the 10 study years, 1997-2006. The RSV-coded hospitalization rate in infants <1 year old was 26.0 per 1000, with no significant difference between study years. The hospitalization rate was highest among infants <3 months old (48.9 per 1000), followed by infants 3 to 5 months old (28.4 per 1000), and lower among those >1 year old (1.8 per 1000). An estimated 132,000 to 172,000 RSV-associated hospitalizations occurred annually in children <5 years of age.
CONCLUSION: RSV hospitalization rates remained steady during 1997 to 2006 and were a substantial burden in the United States, especially among infants and young children. A safe and effective RSV vaccine is needed.

Entities:  

Mesh:

Year:  2012        PMID: 21817948     DOI: 10.1097/INF.0b013e31822e68e6

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  133 in total

1.  Association between breast-feeding and severity of acute viral respiratory tract infection.

Authors:  Shanda Vereen; Tebeb Gebretsadik; Tina V Hartert; Patricia Minton; Kimberly Woodward; Zhouwen Liu; Kecia N Carroll
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

2.  Structural basis for human respiratory syncytial virus NS1-mediated modulation of host responses.

Authors:  Srirupa Chatterjee; Priya Luthra; Ekaterina Esaulova; Eugene Agapov; Benjamin C Yen; Dominika M Borek; Megan R Edwards; Anuradha Mittal; David S Jordan; Parameshwar Ramanan; Martin L Moore; Rohit V Pappu; Michael J Holtzman; Maxim N Artyomov; Christopher F Basler; Gaya K Amarasinghe; Daisy W Leung
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

Review 3.  Structural vaccinology starts to deliver.

Authors:  Philip R Dormitzer; Guido Grandi; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2012-12       Impact factor: 60.633

4.  The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation.

Authors:  Jeanette I Webster Marketon; Jacqueline Corry; Michael N Teng
Journal:  Virology       Date:  2013-11-26       Impact factor: 3.616

5.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

6.  Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Authors:  Lindsay Kim; Brian Rha; Jon S Abramson; Larry J Anderson; Carrie L Byington; Grace L Chen; John DeVincenzo; Kathryn M Edwards; Janet A Englund; Ann R Falsey; Marie R Griffin; Ruth A Karron; Karen G Martin; H Cody Meissner; Flor M Munoz; Andrew T Pavia; Pedro A Piedra; William Schaffner; Eric A F Simões; Rosalyn Singleton; H Keipp Talbot; Edward E Walsh; Jane R Zucker; Susan I Gerber
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

7.  On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus.

Authors:  Edward Goldstein; Hieu H Nguyen; Patrick Liu; Cecile Viboud; Claudia A Steiner; Colin J Worby; Marc Lipsitch
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

8.  Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection.

Authors:  Wouter A A de Steenhuijsen Piters; Santtu Heinonen; Raiza Hasrat; Eleonora Bunsow; Bennett Smith; Maria-Carmen Suarez-Arrabal; Damien Chaussabel; Daniel M Cohen; Elisabeth A M Sanders; Octavio Ramilo; Debby Bogaert; Asuncion Mejias
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

9.  GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.

Authors:  Dharmaraj Samuel; Weimei Xing; Anita Niedziela-Majka; Jinny S Wong; Magdeleine Hung; Katherine M Brendza; Michel Perron; Robert Jordan; David Sperandio; Xiaohong Liu; Richard Mackman; Roman Sakowicz
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Respiratory syncytial virus and reactive airway disease.

Authors:  Matthew T Lotz; Martin L Moore; R Stokes Peebles
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.